This is an old revision of the document!
Precision NanoSystems
Precision NanoSystems is a Canadian biotechnology company based in Vancouver, British Columbia. The company was co-founded by Pieter Cullis, who also co-founded Acuitas Therapeutics.1)
The company develops genetic medicine-based therapies, including “self-assembling” molecules that carry drugs and gene therapies directly into the cells of the human body using DNA and RNA encapsulated in lipid nanoparticles.2) 3) It was launched with assistance from Genome British Columbia.4)
History
COVID-19
On October 23, 2020, Prime Minister Justin Trudeau announced that he had awarded the company $18.2 million from the Government of Canada to Develop an RNA vaccine for COVID-19.5) The funding came from Innovation, Science and Economic Development Canada’s Strategic Innovation Fund (SIF), which focuses on supporting private sector-led vaccine and therapy clinical trials.
1)
Cullis, P. (2019, June 25). Innovation as a Driver for Personalized Medicine in British Columbia. Reboot Communications. https://web.archive.org/web/20210713174744/https://www.rebootcommunications.com/wp-content/uploads/2019/06/Cullis-Kelowna-June-2019.pdf
2)
Create Transformative Medicines. Precision NanoSystems. Retrieved March 8, 2022, from https://archive.ph/GgZY9
3)
Shore, R. (2016, February 25). Vancouver-Based Nanomedicine Startup Targets Genetic Solution to Diseases. Precision NanoSystems. https://archive.ph/QLpEO
4)
Annual Report 2020-2021. Genome BC. Retrieved April 18, 2022, from https://web.archive.org/web/20210703114654/https://www.genomebc.ca/wp-content/uploads/2021/06/GBC-5198-2020-21-AR-FINAL_WEB.pdf
5)
Precision NanoSystems. (2020, October 26). Prime Minister announces LSI spinoff to receive funding to develop an RNA Vaccine for COVID-19 | Life Sciences Institute. University of British Columbia. https://lsi.ubc.ca/2020/10/26/prime-minister-announces-lsi-spinoff-to-receive-funding-to-develop-rna-vaccine-for-covid-19/